Recent Updates
Recently added Catalysts

CP-481,715

Phase 1

Dermatitis, Allergic Contact | Small molecule | Dermatology |Pfizer, Inc.|Last Updated: Jul 25, 2006

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment48
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00141180CP-481,715 Nickel Allergy Study.PHASE1 COMPLETED 48Sep 1, 2003Oct 1, 2005Jul 25, 20065 United States, Denmark
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Effect of CP-481,715 on clinical response and cell infiltration after nickel challenge
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
CP-481,715DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites5

Inclusion Criteria: * A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST. Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,...

Countries:United StatesDenmark
Unlock Eligibility Criteria